Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis’ Ilaris receives European approval recommendation

Novartis’ Ilaris receives European approval recommendation

27th July 2009

Novartis’ Ilaris (canakinumab) drug, which is a biotechnology medicine designed for the treatment of cryopyrin-associated periodic syndrome (CAPS), has been recommended for approval in the EU, it has been announced.

The company explained that CAPS is a lifelong and potentially fatal auto-inflammatory disease and Ilaris has been recommended for those who have the condition and are over the age of four.

Commenting, Trevor Mundel, head of global development at Novartis, said: “By concentrating initially on a rare syndrome with a well-defined disease process such as CAPS, we have been able to demonstrate a clear therapeutic advantage with Ilaris.”

He said that the firm’s focus is now to establish whether or not the drug could offer a new approach to the treatment of other conditions involving a similar underlying process.

Earlier this month, the Food and Drug Administration approved Tekturna HCT (aliskiren and hydrochlorothiazide) as a first-line therapy for patients deemed likely to need several drugs to achieve their blood pressure goals.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.